Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
J Hepatol
2023
78
4
717-730
Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
J Hepatol
2023
79
2
538-551
mRNA 3'UTR lengthening by alternative polyadenylation attenuates inflammatory responses and correlates with virulence of Influenza A virus.
Nat Commun
2023
14
1
Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury.
J Hepatol
2023
79
1
150-166
Hepatitis B Virus Targets Lipid Transport Pathways to Infect Hepatocytes.
Cell Mol Gastroenterol Hepatol
2023
16
2
201-221
Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion.
J Clin Invest
2023
133
21
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
J Hepatol
2023
79
2
296-313
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.
Immunity
2023
56
6
1341-1358.e11
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma.
Nat. Cancer
2023
4
1
81-95
Author Correction: Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.
Nat Med
2022
28
3